Antiepileptic Drugs Under Investigation for Treatment of Focal Epilepsy

Pasquale Striano, Vincenzo Belcastro, Antonietta Coppola, Carlo Minetti, Salvatore Striano

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: Despite optimal medical treatment, up to 30% of patients with epilepsy continue to experience recurrent seizures, and the challenge for new more efficacious and better-tolerated drugs is continuing. New antiepileptic drugs include the evolution of preexisting drugs and new compounds identified through the investigation of additional molecular targets, such as SV2A synaptic vesicle protein, voltage-gated potassium channels, ionotropic and metabotropic glutamate receptors, and gap junctions. AREAS COVERED: We report the available data about different classes of molecules that are in the pipeline for treatment of focal epilepsy. We will present data available on drugs derived from the evolution of preexisting anticonvulsants. We will then report the results on clinical trials performed with new compounds identified through the investigation of additional molecular targets. DISCUSSION: The challenge for new, more efficacious, more specific, and better-tolerated drugs is continuing and a better knowledge of mechanisms underlying epilepsy should represent the guide for future research. The ultimate goal of treatment should be not only to render the patients seizure free but also to improve the quality of life and reduce costs of medical care.

Original languageEnglish
JournalClinical Neuropharmacology
DOIs
Publication statusAccepted/In press - Oct 5 2016

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Antiepileptic Drugs Under Investigation for Treatment of Focal Epilepsy'. Together they form a unique fingerprint.

Cite this